<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064345</url>
  </required_header>
  <id_info>
    <org_study_id>HB0034-01</org_study_id>
    <nct_id>NCT05064345</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate HB0034 in Healthy Adult Participants</brief_title>
  <official_title>A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Huaota Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Huaota Biopharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the safety and tolerability of HB0034 in healthy&#xD;
      subjects following a single dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human (FIH) study of HB0034 to evaluate the safety, tolerability,&#xD;
      pharmacokinetics, and immunogenicity of HB0034.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 3, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with drug related adverse events (AEs)</measure>
    <time_frame>up to 2000 hours</time_frame>
    <description>An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 2000 hours</time_frame>
    <description>The maximum measured concentration of the analysis in plasma</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>up to 2000 hours</time_frame>
    <description>The area under the concentration-time curve of the analysis in plasma over the time interval from 0 extrapolated to infinity</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HB0034 dose group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB0034 dose group 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HB0034 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo for each dose group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB0034</intervention_name>
    <description>Recombinant Humanized Anti-IL-36R Monoclonal antibody</description>
    <arm_group_label>HB0034 dose group 1</arm_group_label>
    <arm_group_label>HB0034 dose group 2</arm_group_label>
    <arm_group_label>HB0034 dose group 3</arm_group_label>
    <arm_group_label>HB0034 dose group 4</arm_group_label>
    <arm_group_label>HB0034 dose group 5</arm_group_label>
    <arm_group_label>HB0034 dose group 6</arm_group_label>
    <arm_group_label>HB0034 dose group 7</arm_group_label>
    <other_name>no other invention names</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Palcebo</description>
    <arm_group_label>Matching placebo for each dose group</arm_group_label>
    <other_name>no other invention names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects age ≥ 18 and ≤ 55 years.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 17.5 and ≤ 32 kg/m².&#xD;
&#xD;
          -  Normal ECG, blood pressure, respiratory rate, temperature, and heart rate, unless the&#xD;
             investigator considers any abnormality to be not clinically significant.&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with GCP and local legislation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric, or neurological disease.&#xD;
&#xD;
          -  Current or history of malignancy.&#xD;
&#xD;
          -  Family history of premature Coronary Heart Disease (CHD)&#xD;
&#xD;
          -  History of clinically significant opportunistic infection (e.g., invasive candidiasis&#xD;
             or pneumocystis pneumonia).&#xD;
&#xD;
          -  Pregnant or Breasting feeding subject. Women with a positive pregnancy test (HCG).&#xD;
&#xD;
          -  Further exclusions criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schwabe</last_name>
    <role>Principal Investigator</role>
    <affiliation>NZCR OpCo limited AKL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang Jingjing</last_name>
    <phone>+86 15002154126</phone>
    <email>jingjing.wang@huaota.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qian Qiaoxia</last_name>
    <phone>+86 18555690860</phone>
    <email>qiaoxia.qian@huaota.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New zealand Clinical Research</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Rowse</last_name>
      <phone>3733474</phone>
      <email>Courtney.rowse@nzcr.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

